| Antigen | No | Weeks after rituximab | CD19 | % CD19 |
| B/Shangai | ||||
| Responders | 3 | 34.3 (26) | 2.7 (2.3) | 0.23 (0.19) |
| Non-responders | 11 | 31.5 (2.8) | 17.3 (25) | 1.26 (1.56) |
| p Value | 0.875 | 0.391 | 0.357 | |
| A/New Caledonian | ||||
| Responders | 5 | 32.8 (21.4) | 18.1 (18.4) | 0.65 (0.35) |
| Non-responders | 9 | 31.8 (24.4) | 12 (25.8) | 1.11 (1.64) |
| p Value | 0.787 | 0.205 | 0.682 | |
| A/California | ||||
| Responders | 3 | 25.3 (23.4) | 9.5 (13.7) | 0.38 (0.45) |
| Non-responders | 11 | 34 (23) | 15.5 (25.2) | 1.21 (1.58) |
| p Value | 0.694 | 0.640 | 0.413 |
Values are mean (SD).